Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| ID | DOID:1380 |
| Name | endometrial cancer |
| Definition | A uterine cancer that is located_in tissues lining the uterus. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:5654 |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
| NCT01379534 | Phase II | Dovitinib | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | Completed | USA | ITA | ESP | 4 |
| NCT01697566 | Phase III | Metformin | An Endometrial Cancer Chemoprevention Study of Metformin | Active, not recruiting | USA | 0 |
| NCT01797523 | Phase II | Letrozole Everolimus Metformin | RAD/Letrozole/Metformin | Active, not recruiting | USA | 0 |
| NCT01874353 | Phase III | Olaparib | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 10 |
| NCT01935934 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT02035787 | Phase I | Metformin | Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | Recruiting | USA | 0 |
| NCT02042495 | Phase II | Metformin | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | Withdrawn | CAN | 0 |
| NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
| NCT02269293 | Phase I | Carboplatin + Paclitaxel + Selinexor | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | Completed | USA | 0 |
| NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | 1 |
| NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
| NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | ESP | 1 |
| NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Recruiting | USA | ITA | ESP | 3 |
| NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Completed | USA | ESP | CAN | BEL | 0 |
| NCT02630823 | Phase I | Carboplatin + Paclitaxel + Pembrolizumab | MK-3475 Immunotherapy in Endometrial Carcinoma | Completed | USA | 0 |
| NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
| NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
| NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Completed | USA | 0 |
| NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
| NCT02684227 | Phase II | Carboplatin + Enzalutamide + Paclitaxel | Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT02715284 | Phase I | Dostarlimab-gxly | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Recruiting | USA | ITA | FRA | ESP | CAN | 4 |
| NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
| NCT02728258 | Phase II | Copanlisib | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | Completed | USA | 0 |
| NCT02728830 | Phase I | Pembrolizumab | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Unknown status | USA | 0 |
| NCT02788708 | Phase I | Lenvatinib + Paclitaxel | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Completed | USA | 0 |
| NCT02899793 | Phase II | Pembrolizumab | Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT02912572 | Phase II | Avelumab + Talazoparib Avelumab Avelumab + Axitinib | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
| NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03016338 | Phase II | Niraparib | Study of Niraparib in Recurrent Endometrial Cancer | Active, not recruiting | CAN | 0 |
| NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
| NCT03099499 | Phase II | ONC201 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | Suspended | USA | 0 |
| NCT03120624 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | ESP | BEL | 1 |
| NCT03162627 | Phase I | Olaparib + Selumetinib | Selumetinib and Olaparib in Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | FRA | DEU | CAN | 5 |
| NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Recruiting | 1 | |
| NCT03300557 | Phase II | Exemestane | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03310567 | Phase II | Epacadostat + Pembrolizumab | A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma | Withdrawn | USA | 0 |
| NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Active, not recruiting | USA | 0 |
| NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Active, not recruiting | FRA | BEL | 0 |
| NCT03394027 | Phase II | ONC201 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | Completed | USA | 0 |
| NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | FRA | ESP | 1 |
| NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Active, not recruiting | USA | 1 |
| NCT03474640 | Phase I | Toripalimab | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Active, not recruiting | USA | 0 |
| NCT03485729 | Phase II | ONC201 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Active, not recruiting | USA | 0 |
| NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
| NCT03552471 | Phase I | Mirvetuximab Soravtansine + Rucaparib | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT03555422 | Phase III | Selinexor | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) | Active, not recruiting | USA | ITA | ESP | DEU | CAN | BEL | 4 |
| NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
| NCT03572478 | Phase Ib/II | Nivolumab + Rucaparib Nivolumab Rucaparib | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Terminated | USA | 0 |
| NCT03617679 | Phase I | Rucaparib | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | 1 |
| NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | 1 |
| NCT03643510 | Phase II | Abemaciclib + Fulvestrant | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | Recruiting | USA | 0 |
| NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03671811 | Phase II | Megestrol acetate + Pterostilbene Megestrol acetate | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | Active, not recruiting | USA | 0 |
| NCT03675893 | Phase II | Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 | Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer | Recruiting | USA | 0 |
| NCT03745950 | Phase II | Olaparib | UTOLA: UTerin OLAparib (UTOLA) | Active, not recruiting | FRA | 0 |
| NCT03748186 | Phase I | STRO-002 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Recruiting | USA | ESP | 0 |
| NCT03835819 | Phase II | Mirvetuximab Soravtansine + Pembrolizumab | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | Recruiting | USA | 0 |
| NCT03905148 | Phase Ib/II | Lifirafenib + PD-0325901 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | Recruiting | USA | 1 |
| NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | 2 |
| NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Recruiting | USA | FRA | ESP | CAN | BEL | 3 |
| NCT03968406 | Phase I | Talazoparib | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Recruiting | USA | 0 |
| NCT03981796 | Phase III | Carboplatin + Paclitaxel Carboplatin + Dostarlimab-gxly + Paclitaxel | A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) | Active, not recruiting | USA | ITA | ESP | DEU | CAN | BEL | 14 |
| NCT04008797 | Phase I | Lenvatinib E7386 + Lenvatinib | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | USA | 3 |
| NCT04044859 | Phase I | ADP-A2M4 cells ADP-A2M4 cells + Pembrolizumab ADP-A2M4 cells + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Recruiting | USA | ESP | CAN | BEL | 0 |
| NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
| NCT04145622 | Phase Ib/II | DS-7300a | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
| NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Recruiting | USA | 4 |
| NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Recruiting | FRA | 0 |
| NCT04188548 | Phase I | Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) | Active, not recruiting | USA | FRA | ESP | BEL | 4 |
| NCT04197219 | Phase II | Axitinib + Pembrolizumab | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Withdrawn | 0 | |
| NCT04214067 | Phase III | Pembrolizumab | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | Active, not recruiting | USA | 1 |
| NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients | Recruiting | USA | 0 |
| NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | FRA | 1 |
| NCT04319757 | Phase I | ACE1702 + Cyclophosphamide + Fludarabine | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | Recruiting | USA | 1 |
| NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
| NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | 1 |
| NCT04463771 | Phase II | Pemigatinib + Retifanlimab Epacadostat + Retifanlimab Retifanlimab | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) | Recruiting | USA | ITA | FRA | DEU | BEL | 3 |
| NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Active, not recruiting | USA | ITA | ESP | CAN | BEL | 10 |
| NCT04491942 | Phase I | BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Recruiting | USA | CAN | 0 |
| NCT04498520 | Phase I | Abexinostat + Fulvestrant + Palbociclib | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Withdrawn | 0 | |
| NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
| NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Active, not recruiting | USA | 0 |
| NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
| NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | FRA | ESP | CAN | 0 |
| NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | 1 |
| NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
| NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Recruiting | USA | 0 |
| NCT04774419 | Phase II | Dostarlimab-gxly | Radiation and Dostarlimab in People With Endometrial Cancer After They Receive Surgery | Recruiting | USA | 0 |
| NCT04781088 | Phase II | Lenvatinib + Paclitaxel + Pembrolizumab | Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
| NCT04787042 | Phase Ib/II | ST-067 | Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067 | Recruiting | USA | 0 |
| NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ESP | 1 |
| NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Recruiting | USA | 0 |
| NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
| NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 9 |
| NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
| NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | 1 | |
| NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Recruiting | USA | 1 |
| NCT05082025 | Phase II | Copanlisib + Fulvestrant | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | Recruiting | USA | 0 |
| NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Recruiting | FRA | 1 |
| NCT05112601 | Phase II | Ipilimumab + Nivolumab Nivolumab | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Recruiting | USA | 0 |
| NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | ESP | CAN | BEL | 7 |
| NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05229900 | Phase I | SGN-ALPV | A Study of SGN-ALPV in Advanced Solid Tumors | Recruiting | USA | ESP | CAN | 2 |
| NCT05252416 | Phase Ib/II | BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant | (VELA) Study of BLU-222 in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05262530 | Phase Ib/II | BNT142 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6 Positive Solid Tumors | Recruiting | USA | ESP | 1 |
| NCT05263492 | Phase II | Lenvatinib + Pembrolizumab | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | Recruiting | USA | 0 |
| NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 1 |
| NCT05306444 | Phase I | HBM7008 | HBM7008 -Study on Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Active, not recruiting | USA | 1 |
| NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
| NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05419817 | Phase II | Pembrolizumab + Sitravatinib | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | Withdrawn | 0 | |
| NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Recruiting | USA | 0 |
| NCT05523440 | Phase II | Bevacizumab + Niraparib Niraparib | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation (ARID1A) | Recruiting | USA | 0 |
| NCT05527184 | Phase I | IMGN151 | First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Recruiting | USA | 0 |
| NCT05554328 | Phase II | Selumetinib Olaparib + Selumetinib | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Recruiting | USA | 0 |
| NCT05572684 | Phase Ib/II | NC410 + Pembrolizumab | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05579366 | Phase Ib/II | PRO1184 | PRO1184 for Advanced Solid Tumors (PRO1184-001) | Recruiting | USA | 0 |
| NCT05634499 | Phase II | Giredestrant | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA) | Recruiting | USA | CAN | 1 |
| NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | 1 | |
| NCT05650203 | Phase I | JS006 + JS009 + Toripalimab JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
| NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | 1 | |
| NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Not yet recruiting | USA | 0 |
| NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
| NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | 0 |
| NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Recruiting | USA | 0 |
| NCT05761951 | Phase II | DKN-01 + Pembrolizumab | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | Not yet recruiting | USA | 0 |